Physician profile
Patrick Hagen
NPI 1265725592
$141,252.58
in general payments reported to CMS, 2019-2025
17 companies · $15K in 2025
The $15K reported for 2025 was more than what 91% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,462 · 2020: $5,938 · 2021: $10K · 2022: $30K · 2023: $49K · 2024: $23K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $64K · Consulting Fee: $17K · Travel and Lodging: $3,105 · Food and Beverage: $2,751 · Education: $63.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $63,979.00 |
| Consulting Fee | $17,006.00 |
| Travel and Lodging | $3,104.77 |
| Food and Beverage | $2,751.04 |
| Education | $63.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $87,472.44 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $28,357.29 | 2022-2024 | Pomalyst |
| Celgene Corporation | $16,616.28 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $5,888.00 | 2021-2022 | |
| Adaptive Biotechnologies Corporation | $1,670.22 | 2020-2025 | Clonoseq |
| National Marrow Donor Program | $695.78 | 2022-2025 | |
| Pfizer INC. | $201.78 | 2023-2025 | |
| Akcea Therapeutics, INC. | $121.60 | 2019 | |
| Novartis Pharmaceuticals Corporation | $85.28 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.20 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $43.25 | 2025 | Enhertu |
| Merck Sharp & Dohme LLC | $19.81 | 2023 | Prevymis |
| Glaxosmithkline, LLC. | $13.20 | 2021 | |
| Karyopharm Therapeutics INC. | $12.45 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Hagen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.